Consultant Report Summaries, May

Part
01
of two
Part
01

Consultant Report Summaries, May, Part 1

Responding to COVID-19 by the Monitor Institute by Deloitte.

Responding to COVID-19 Resources for Nonprofits was published by the Monitor Institute by Deloitte on May 14th, 2020. The report focuses on Nonprofit Leaders, Philanthropic Funders, and Nonprofit Board Members. The relevant topics covered are hospital structure, pharmacy staffing, telemedicine, and home healthcare.

Hospital Structure

  • In order to meet the staffing demands during the pandemic, some states are waiving the inter-state licensing requirements for medical professionals. This helps in states that are struggling to meet the demands.

Pharmacy Staffing

Telemedicine

  • Some states have changed requirements for telehealth licensures, this has created a greater need for telehealth professionals and increased hiring demands.
  • PlushCare, a telehealth company has seen a 70% increase in appointments and experience a need for twice as many doctors during the pandemic.

Home Healthcare

COVID-19 Response Capabilities Rapidly Combating COVID-19 with resilience Pharmacy Services: Inpatient/Outpatient

COVID-19 Response Capabilities Rapidly Combating COVID-19 with resilience Pharmacy Services: Inpatient/Outpatient was published on April 15th, 2020 by Deloitte. The report focuses on pharmacy services on pharmacy services, and the changes required during the pandemic.

Pharmacy Services

Part
02
of two
Part
02

Consultant Report Summaries, May, Part 2

The report COVID-19 implications for life sciences focused on the research and development side of the pharma and medtech companies with no mention of the topics of interest. A Human-First Approach as You Recover and Thrive by Deloitte provides insight into the increase in telemedicine during the pandemic.

COVID-19 Implications for Life Sciences R&D: Recovery and the Next Normal

  • COVID-19 implications for life sciences R&D: Recovery and the next normal was published by McKinsey and Company in May 2020. The report focuses on medtech and pharma research and development, and preparing during the pandemic and after.
  • COVID-19 has brought pharma and medtech companies to the forefront. The landscape for clinical trials and the delivery have changed since the pandemic began and will likely continue to change after the pandemic.
  • Site issues due to hospital capacity has led to the use of alternative sites for clinical trials including pharmacies, and retail clinics.
  • Digital tools are being employed and are replacing in-person interactions. Depending on the success of the virtual tools this may continue after the pandemic. 95% of medical science liaisons are engaging with physicians remotely as of April.
  • The report focuses solely on the research and development side of the pharma and medtech industry and not on the relevant research topics of interest.

A Human-First Approach as You Recover and Thrive

  • A Human-First Approach as You Recover and Thrive on May 15th, 2020 by Deloitte. The report focuses on how companies can respond, recover and thrive. Organizations need to focus on understand customers, bringing empathy and humanity, embracing digital acceleration, be open to collaborations, and be agile and adapt. The report includes information on telemedicine.

Telemedicine

  • During the pandemic doctors and patients have had to figure out how to maintain care while being told by public health officials to avoid in-person visits. This has led to a wider implementation of telemedicine.
  • Video links are being used to monitor COVID-19 patients who do not require in person care and for people needing routine care.
  • The increase in telemedicine has also impacted insurers and healthcare organizations who have been forced to adapt to the situation and eliminate hurdles that were slowing the adoption in the past.
  • Adoption of telemedicine has been forced during the pandemic, but the cost and time saving to patients and doctors may shape the future of in-person visits and make telemedicine a permanent solution for many.
Sources
Sources